
|Articles|February 24, 2014
- Gastrointestinal Cancers (Issue 1)
- Volume 1
- Issue 1
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Author(s)Robert L. Fine, MD
Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Advertisement
Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Read more abouta hedgehog pathway inhibitor for the treatment of advanced pancreatic cancer > >
Articles in this issue
over 12 years ago
The Identification of Molecular Subtypes of Gastric Cancerover 12 years ago
Ramucirumab Combo Increases Survival in Gastric Cancerover 12 years ago
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Dataover 12 years ago
New Standard of Neoadjuvant Care for Rectal Cancer Establishedover 12 years ago
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancerover 12 years ago
The Treatment of Advanced Colorectal CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































